Occlutech is a leading global provider of minimally invasive structural heart disease (SHD) devices. With a mission to improve the quality of life for people born with or developing heart defects, Occlutech develops, manufactures, and commercializes a comprehensive portfolio of occluders, implants, and accessories. The company is dedicated to innovation, research, and clinical excellence, offering solutions for conditions such as Atrial Septal Defects (ASD), Patent Foramen Ovale (PFO), Left Atrial Appendage (LAA) closure, and Ventricular Septal Defects (VSD). Occlutech products are sold in over 90 countries, supported by a strong global presence and a commitment to patient care and advancing medical technology.
The headquarters serves as the central hub for Occlutech's global operations, encompassing strategic management, research and development leadership, global marketing, finance, and core administrative functions.
The facility likely incorporates modern office spaces and potentially advanced R&D laboratories, designed to foster innovation and collaboration in medical device development.
Occlutech fosters a work culture centered on innovation, patient well-being, and scientific excellence. It emphasizes collaboration, ethical practices, and a commitment to developing high-quality, life-saving medical devices.
The Helsingborg headquarters is pivotal for driving Occlutech's strategic vision, coordinating its international operations, advancing its product pipeline, and maintaining its position as a leader in structural heart disease solutions.
Occlutech maintains a significant global footprint, with functions such as research and development, manufacturing, sales, marketing, clinical affairs, and distribution supported internationally. The company's innovative structural heart disease products are available in over 90 countries, facilitated through a network of direct sales teams and dedicated distribution partners, ensuring broad access for patients and healthcare providers worldwide.
Landskronavägen 2
Helsingborg
Skåne
Sweden
Address: Winzerlaer Straße 2, 07745 Jena, Germany
Serves as a critical hub for the production and technological advancement of Occlutech's cardiac devices, primarily supporting the European market and contributing significantly to the company's global supply chain.
Address: 10 N. Martingale Road, Suite 400, Schaumburg, IL 60173, USA
Focuses on expanding Occlutech's market presence in the United States and Canada by providing clinical expertise, product training, and customer support to healthcare professionals utilizing their structural heart devices.
Address: Eyüp Sultan Mah. İbni Sina Cad. No:12 Sancaktepe, Istanbul, Turkey
Supports the manufacturing and supply of Occlutech's devices, playing a role in the company's strategy to serve markets in the region and globally.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Occlutech' leadership includes:
Occlutech has been backed by several prominent investors over the years, including:
In the past year, Occlutech experienced a key leadership transition with the appointment of a new Chief Executive Officer, Sabine Steiner, poised to guide the company's strategic growth and innovation in the structural heart device sector.
Discover the tools Occlutech uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Occlutech generally utilizes standard corporate email formats. The most common patterns are likely 'first.last@occlutech.com' or 'firstinitiallast@occlutech.com'.
first.last@occlutech.com (e.g., jane.doe@occlutech.com) or f[last]@occlutech.com (e.g., jdoe@occlutech.com)
Format
sabine.steiner@occlutech.com
Example
80%
Success rate
Business Wire • September 21, 2023
Occlutech announced the enrollment of the first U.S. patient in its FROST-PFO clinical study. The study is designed to evaluate the safety and efficacy of the Occlutech PFO Occluder for recurrent stroke prevention in patients with a PFO. This marks a significant milestone in Occlutech's efforts to bring its innovative PFO closure technology to patients in the United States....more
PR Newswire • March 2, 2023
Occlutech announced the appointment of Sabine Steiner as its new Chief Executive Officer, effective immediately. Ms. Steiner brings over 20 years of extensive experience in the global medical device industry, succeeding Tor Peters. She is expected to lead Occlutech into its next phase of growth and innovation....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Occlutech, are just a search away.